Benzinga.com

Novo Nordisk Files FDA Application For Weekly Combination Obesity Shot

Novo Nordisk A/S (NYSE: NVO) on Thursday submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for once-weekly CagriSema. The application covers CagriSema for use with ...
BioSpace

Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management

PLAINSBORO, N.J. and BAGSVÆRD, Denmark, Dec. 18, 2025 /PRNewswire/ -- Today, Novo Nordisk announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ...
Seeking Alpha

Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management

CagriSema 2.4 mg/2.4 mg is an investigational fixed-dose injectable medicine that combines the novel amylin analogue, cagrilintide, with semaglutide to target complementary obesity-related pathways ...
Daily Mail

Pam Bondi's lawyers claim halting Trump's ballroom would create national security risk ... as secret file reveals East Wing demolition was plotted for months

Attorney General Pam Bondi's lawyers argued in court this week that President Donald Trump's ballroom project must proceed for unspecified national security concerns. Last week, the National Trust for ...